Advances in the role of pituitary adenylate cyclase-activating peptide in migraine
10.3760/cma.j.cn113694-20250102-00005
- VernacularTitle:垂体腺苷酸环化酶激活肽在偏头痛中的作用机制研究进展
- Author:
Wenlu YE
1
;
Xuan XU
1
;
Yixian HUANG
1
Author Information
1. 苏州大学附属第二医院神经内科，苏州 215004
- Publication Type:Journal Article
- Keywords:
Pituitary adenylate cyclase-activating polypeptide;
Migraine disorders;
Calcitonin gene-related peptide;
Monoclonal antibody
- From:
Chinese Journal of Neurology
2025;58(9):1011-1017
- CountryChina
- Language:Chinese
-
Abstract:
Migraine is a chronic brain dysfunction disorder characterized by recurrent unilateral or bilateral moderate-to-severe throbbing headaches, often accompanied by symptoms such as nausea, vomiting, photophobia, and phonophobia. Pituitary adenylate cyclase-activating polypeptide (PACAP) is a vasodilatory peptide that plays a significant role in the pathogenesis of migraine through mechanisms similar to, yet independent of, calcitonin gene-related peptide. With in-depth research on PACAP′s involvement in migraine pathogenesis, drugs targeting PACAP and its receptors have been progressively developed and entered clinical trials. This article outlines the structure and biological characteristics of PACAP and its receptors, summarizes their roles in different stages of migraine pathogenesis, and discusses their current status and prospects as biomarkers and therapeutic targets for migraine to provide new insights into the mechanisms, diagnosis, and treatment of migraine.
